会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 22. 发明授权
    • Spiro-piperidine derivatives and their use as tachykinin antagonists
    • 螺哌啶衍生物及其作为速激肽拮抗剂的用途
    • US6060469A
    • 2000-05-09
    • US77063
    • 1998-05-18
    • Raymond BakerTimothy HarrisonChristopher John SwainBrian John Williams
    • Raymond BakerTimothy HarrisonChristopher John SwainBrian John Williams
    • A61K31/00A61K31/445A61K31/4465A61K31/4523A61K31/4525A61K31/454A61K31/505A61K31/506A61P1/00A61P1/08A61P25/06A61P29/00A61P43/00C07D491/10C07D491/107C07D471/10
    • C07D491/10
    • The present invention relates to compounds of formula (I), ##STR1## wherein R.sup.1 represents halogen, hydroxy, C.sub.1-6 alkyl group optionally substituted by one or three fluorine atoms, C.sub.1-6 alkoxy group optionally substituted by one to three fluorine atoms, or C.sub.1-6 alkylthio optionally substituted by one to three fluorine atoms; R.sup.2 represents hydrogen, halogen, C.sub.1-6 alkyl or C.sub.1-6 alkoxy; or when R.sup.2 is adjacent to R.sup.1, they may be joined together such that there is formed a 5- or 6-membered saturated or unsaturated ring containing one or two oxygen atoms; R.sup.3 represents an optionally substituted 5- or 6-membered aromatic heterocyclic group containing 1, 2, 3 or 4 heteroatoms, selected from nitrogen, oxygen and sulphur; m is 0-3 and n is 0-3, with the proviso that the sum total of m+n is 2 or 3; p is zero or 1; q is 1 or 2; and when m is 1 and n is 1 or 2, the broken line represents an optional double bond; R.sup.4, R.sup.5, R.sup.6, R.sup.9 and R.sup.10 are a variety of substituents defined in the specification; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, emesis and postherpetic neuralgia.
    • PCT No.PCT / GB96 / 02853 Sec。 371日期1998年5月18日 102(e)日期1998年5月18日PCT提交1996年11月20日PCT公布。 公开号WO97 / 19084 日期:1997年5月29日本发明涉及式(I)化合物,其中R 1表示卤素,羟基,任选被一个或三个氟原子取代的C 1-6烷基,任选被一至三个氟原子取代的C 1-6烷氧基,或 任选被一至三个氟原子取代的C 1-6烷硫基; R 2表示氢,卤素,C 1-6烷基或C 1-6烷氧基; 或者当R 2与R 1相邻时,它们可以连接在一起,使得形成含有一个或两个氧原子的5-或6-元饱和或不饱和环; R3表示含有1,2,3或4个选自氮,氧和硫的杂原子的任选取代的5-或6-元芳族杂环基; m为0-3,n为0-3,条件是m + n的总和为2或3; p为零或1; q为1或2; 当m为1且n为1或2时,虚线表示任选的双键; R4,R5,R6,R9和R10是说明书中定义的各种取代基; 或其药学上可接受的盐。 该化合物特别用于治疗或预防疼痛,炎症,呕吐和带状疱疹后神经痛。
    • 29. 发明授权
    • Morpholine derivatives and their use as therapeutic agents
    • 吗啉衍生物及其作为治疗剂的用途
    • US5968934A
    • 1999-10-19
    • US68818
    • 1998-05-14
    • Christopher John SwainMartin Richard TeallBrian John Williams
    • Christopher John SwainMartin Richard TeallBrian John Williams
    • A61K31/00A61K31/535A61K31/5375A61K31/5377A61P25/06A61P29/00A61P43/00C07D413/04C07D417/04
    • C07D413/04C07D417/04
    • The present invention relates to compounds of formula (I) ##STR1## wherein X is a 5- or 6-membered C-linked heteroaromatic ring containing 1 to 4 nitrogen atoms and optionally containing in the ring one oxygen or sulphur atom; Y is a group of the formula --(CH.sub.2).sub.n NR.sup.6 R.sup.7 or a methylene- or ethylene-linked imidazolyl group; Z is hydrogen or C.sub.1-4 alkyl optionally substituted by a hydroxy group; R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.9a and R.sup.9b are a variety of substituents; R.sup.6 is hydrogen, C.sub.1-6 akyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, or C.sub.2-4 akyl substituted by C.sub.1-4 alkoxy or hydroxy, R.sup.7 is hydrogen, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, or C.sub.2-4 alkyl substituted by one or two substituents selected from C.sub.1-4 alkoxy, hydroxy or a 4-, 5- or 6-membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S; or R.sup.6 and R.sup.7, together with the nitrogen atom to which they are attached, form a saturated or partially saturated heterocyclic ring or a non-aromatic azabicyclic ring system; and n is zero, 1 or 2; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherapeutic neuralgia.
    • PCT No.PCT / GB96 / 02766 Sec。 371日期:1998年5月14日 102(e)日期1998年5月14日PCT 1996年11月13日PCT公布。 WO97 / 18206 PCT公开号 日期:1997年5月22日本发明涉及式(I)化合物,其中X为含有1至4个氮原子且任选地在环中含有一个氧或硫原子的5-或6-元C-连接的杂芳环; Y是式 - (CH2)nNR6R7或亚甲基或乙烯连接的咪唑基的基团; Z是氢或任选被羟基取代的C 1-4烷基; R1,R2,R3,R4,R5,R9a和R9b是多种取代基; R 6是氢,C 1-6烷基,C 3-7环烷基,C 3-7环烷基C 1-4烷基,苯基或被C 1-4烷氧基或羟基取代的C 2-4烷基,R 7是氢,C 1-6烷基,C 3-7环烷基,C 3-7环烷基C 1-4烷基, 苯基或被一个或两个选自C 1-4烷氧基,羟基或含有一个或两个选自N,O和S的杂原子的4-,5-或6-元杂脂肪族环取代的C 2-4烷基; 或R6和R7与它们所连接的氮原子一起形成饱和或部分饱和的杂环或非芳族氮杂双环体系; n为零,1或2; 或其药学上可接受的盐。 该化合物特别用于治疗或预防疼痛,炎症,偏头痛,呕吐和治疗后神经痛。